Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18237566 | 0.76 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21987946 | 0.74 | ALDH1A1 (0.41) | ALDH1A1HPGDHTR2AHTR1ADRD2 | |
| SCHEMBL23793158 | 0.72 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL23782815 | 0.71 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2HPGDKDM4EHSD17B10 | |
| SCHEMBL21987941 | 0.69 | CDC7 (0.36) | ALDH1A1HTR2AHTR1ADRD2 | |
| SCHEMBL19152921 | 0.68 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2HPGDPOLBHTR2A | |
| SCHEMBL1917570 | 0.66 | KDM4E (0.48) | ALDH1A1SMN1; SMN2HPGDKDM4EHSD17B10 | |
| SCHEMBL10426958 | 0.64 | TDP1 (0.53) | ALDH1A1SMN1; SMN2POLBKDM4EKMT2A | |
| SCHEMBL19002374 | 0.61 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HPGDPOLBHSD17B10 | |
| SCHEMBL1918668 | 0.61 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2HPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20220306635-A1 | TDO2 Inhibitors | GENENTECH, INC. | 2022-09-29 | — | — | US | disclosed |
| CN-115010712-A | TDO2 inhibitors | 基因泰克公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-110072864-B | TDO2 inhibitors | 基因泰克公司 | 2022-05-27 | — | — | CN | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| CN-110072864-A | TDO2 INHIBITORS | 基因泰克公司 | 2019-07-30 | — | — | CN | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20070099991-A1 | SELECTIVE RXR LIGANDS | HAFFNER CURT D | 2007-05-03 | — | — | US | disclosed |
| US-7173134-B2 | Selective RXR ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040198980-A1 | Selective rxr ligands | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1430042-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SmithKline Beecham Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027090-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | ALDH1A1 1758/4885SMN1; SMN2 4338/4885HPGD 482/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ALDH1A1 2151/4885SMN1; SMN2 506/4885HPGD 4543/4885 |
| US-20040198980-A1 | Selective rxr ligands | RXRA, RXRB, RXRG | ALDH1A1 2289/4885SMN1; SMN2 3917/4885HPGD 1486/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | ALDH1A1 2096/4885SMN1; SMN2 4620/4885HPGD 295/4885 |
| US-20070099991-A1 | SELECTIVE RXR LIGANDS | RXRB, RXRA, RXRG | ALDH1A1 1916/4885SMN1; SMN2 3986/4885HPGD 1124/4885 |
| US-20220306635-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | ALDH1A1 1849/4885SMN1; SMN2 4456/4885HPGD 479/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | ALDH1A1 2096/4885SMN1; SMN2 4620/4885HPGD 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.